Krebs H B
Obstet Gynecol. 1986 Dec;68(6):837-41.
Ninety patients were studied in a controlled, randomized fashion to evaluate the effectiveness of topical 5-fluorouracil in reducing the recurrence rate of human papillomavirus-associated lesions of the vulva and vagina. Following complete ablation of the lesions by one or more treatment modalities, 45 patients applied a single dose of 5% 5-fluorouracil cream biweekly to the vagina and/or vulva for at least six months. Forty-five patients used no prophylactic 5-fluorouracil cream. Patients in both groups were comparable with regard to race, age, and immune status, as well as the number, location, duration, clinical appearance, histology, and prior treatment of the lesions. Six patients (13%) with 5-fluorouracil prophylaxis and 17 (38%) without additional treatment (P less than .01) developed recurrent lesions during a follow-up time of nine to 22 months (mean = 14.4 months). Maintenance therapy with 5-fluorouracil was most effective in women with multiple lesions, multiple organ involvement, or with a depressed immune system.
对90名患者进行了对照随机研究，以评估局部使用5-氟尿嘧啶在降低人乳头瘤病毒相关的外阴和阴道病变复发率方面的有效性。在通过一种或多种治疗方式完全切除病变后，45名患者每两周在阴道和/或外阴涂抹一剂5%的5-氟尿嘧啶乳膏，持续至少六个月。45名患者未使用预防性5-氟尿嘧啶乳膏。两组患者在种族、年龄、免疫状态以及病变的数量、位置、持续时间、临床表现、组织学和既往治疗方面具有可比性。在9至22个月（平均 = 14.4个月）的随访期内，接受5-氟尿嘧啶预防的6名患者（占13%）和未接受额外治疗的17名患者（占38%）出现了复发性病变（P小于0.01）。5-氟尿嘧啶维持治疗对患有多处病变、多器官受累或免疫系统低下的女性最为有效。
